Cargando…

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

Monitoring of anti-drug antibodies in patients on ustekinumab is not routinely recommended in patients with inflammatory bowel disease (IBD) due to low rates of immunogenicity. Aim of study: The purpose of this study was to investigate the relationship between anti-drug antibodies detected by a drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roblin, Xavier, Duru, Gérard, Papamichael, Konstantinos, Cheifetz, Adam S., Kwiatek, Sandy, Berger, Anne-Emmanuelle, Barrau, Mathilde, Waeckel, Louis, Nancey, Stephane, Paul, Stephane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219534/ https://www.ncbi.nlm.nih.gov/pubmed/37240501 http://dx.doi.org/10.3390/jcm12103395

Ejemplares similares

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10(®) to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
por: Berger, Anne Emmanuelle, et al.
Publicado: (2022)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
por: Deyhim, Tina, et al.
Publicado: (2023)

Use of imaging modalities for decision-making in inflammatory bowel disease
por: Nancey, Stéphane, et al.
Publicado: (2023)

Alteration of microbiota antibody‐mediated immune selection contributes to dysbiosis in inflammatory bowel diseases
por: Michaud, Eva, et al.
Publicado: (2022)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

A primer on common supplements and dietary measures used by patients with inflammatory bowel disease
por: Minhas, Hadi J, et al.
Publicado: (2023)

Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature
por: Venturin, C., et al.
Publicado: (2017)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
por: Papamichael, Konstantinos, et al.
Publicado: (2017)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
por: Cherry, Mohamad, et al.
Publicado: (2020)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Increased Immunity against the Oral Germs Porphyromonas gingivalis and Prevotella intermedia in Different Categories of Juvenile Idiopathic Arthritis
por: Zekre, Franck, et al.
Publicado: (2022)

The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate
por: Mojtahed Poor, Sorwe, et al.
Publicado: (2023)

Prior COVID-19 Immunization Does Not Cause IgA- or IgG-Dependent Enhancement of SARS-CoV-2 Infection
por: Yaugel-Novoa, Melyssa, et al.
Publicado: (2023)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Inflammatory bowel disease: towards a personalized medicine
por: Flamant, Mathurin, et al.
Publicado: (2018)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing
por: Argüelles-Arias, Federico, et al.
Publicado: (2023)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants
por: Vogrig, Manon, et al.
Publicado: (2022)

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease
por: Kono, Masashi, et al.
Publicado: (2019)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
por: Soleto, Irene, et al.
Publicado: (2023)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
por: Jentzer, Alexandre, et al.
Publicado: (2020)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)

Ustekinumab-induced autoimmune hepatitis: a case report
por: Samah, Ali Said, et al.
Publicado: (2023)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Efficacy and safety of ustekinumab in adolescents
por: Kellen, Roselyn, et al.
Publicado: (2016)

Ustekinumab-associated disseminated verrucae
por: Anderson, Mary E., et al.
Publicado: (2018)

A192 EFFICACY OF USTEKINUMAB IN SMALL BOWEL STRICTURES OF FIBROSTENOTIC CROHN'S DISEASE AS ASSESSED BY INTESTINAL ULTRASOUND
por: St-Pierre, J, et al.
Publicado: (2023)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d6tq77lgf650jq1svmndt8avjt